F.A.Z. Konferenz 15. Jahrestagung House of Pharma & Healthcare

F.A.Z. Konferenz 15. Jahrestagung House of Pharma & Healthcare
Go back

Die Jahrestagung House of Pharma & Healthcare ist eine der führenden Pharmakonferenzen Deutschlands.

Sie bietet Experten aus allen Bereichen der Gesundheits- und Pharmabranche die Gelegenheit zur Information und Vernetzung, denn Sie bindet im Programm alle Akteure des Gesundheitswesens ein: Politiker wie Patienten, Ärzte und Apotheker, Krankenkassen und Zulassungsbehörden, aber auch Unternehmen, Universitäten und Forschungsinstitute. Im Rahmen von zahlreichen Vorträgen, Podiumsdiskussionen und Workshop-Sessions wird intensiv nach Lösungen aktueller Probleme der Arzneimittelforschung, Patientenversorgung und Gesundheitspolitik gesucht.

Exklusivitätsvorbehalt

Die Jahrestagung House of Pharma & Healthcare richtet sich an Entscheiderinnen und Entscheider aus pharmazeutischer Industrie und Biotechnologie, Pharmaforschung und klinischer Entwicklung, Gesundheitswesen und Krankenkassen, Medizintechnik und Diagnostik, Politik und Regulatorik, Verbänden und Organisationen sowie HealthTech- und BioTech-Unternehmen. Für diesen Personenkreis ist die Teilnahme kostenfrei.

 

Free Participation for BioRN members.

Please contact Nicole Hecht (nh(at)biorn.org) for the Discount Code / Registration Form and more Information.

register now

Our latest News

discover more
BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

Ridgefield, CT, USA, July 9, 2026 – BioMed X, a leading innovation engine for pharma, and Boehringer Ingelheim today announced the launch of a new research team at XSeed Labs, the established innovation incubator embedded within Boehringer’s U.S. R&D headquarters in Ridgefield, Connecticut. The newly established research team, Team NIB (New Platform for Next-Generation Intraocular […]

read more
Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Researchers at Heidelberg University’s Faculty of Medicine are investigating a new care model for older adults with mild strokes at the Heidelberg University Hospital’s Department of Neurology. The Joint Federal Committee (G-BA) is funding the ARTIFICE study with approximately 2.4 million euros. Full Text in German below. Klinische Studie zu leichtem Schlaganfall: stationär oder ambulant […]

read more
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline

VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline

Ardigen platform supports VERAXA’s in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engagers (TCEs) and antibody drug conjugates (ADCs) ZURICH, SWITZERLAND – July 13, 2026 — VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced a collaboration with Ardigen S.A., an AI-driven computational partner for modern […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp